《新股消息》德视佳(01846.HK):看到中国市场庞大 将在重庆及成都开设诊所
德视佳(01846.HK)主席兼行政总裁Jorn Slot Jorgensen在上市仪式後表示,很难找到最合适的上市时机,但看到眼科手术及眼科护理是一个很好的市场,因此打算在此时上市,乐见投资者对德国的品牌充满信心。
至於选择在港上市是因为觉得香港是中国的桥梁,仍相信香港会在全球扮演重要的角色。
副总裁(丹麦)Jannik Jonas Slot Jorgensen则指,目前中国有90%的年青人有近视,看到中国市场庞大。公司现时在中国有六家诊所,并计划每年最少开两间新诊所,现已确定有两间诊所将开在重庆及成都,会将欧洲的技术应用於中国诊所之中。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.